Theseus Pharmaceuticals, Inc.
THRX | $4.06 0.49% 0
|
(0.0% 1d) (0.0% 1m) (-58.2% 1y) (0.0% 2d) (0.0% 3d) (0.1% 7d) (-100.0% volume)
Earnings Calendar: 2023-11-02
Market Cap: $ 179,574,348
https://theseusrx.com
Sec Filling | Patents | 2021 employees
Theseus is a biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development and commercialization of transformative targeted therapies. Theseus is developing next-generation tyrosine kinase inhibitors (TKIs): "pan-variant" targeted therapies that address all major drug resistance mutations. Theseus' lead product candidate, THE-630, is a pan-variant KIT inhibitor for the treatment of patients with advanced gastrointestinal stromal tumors (GIST), whose cancer has developed resistance to earlier lines of kinase inhibitor therapy. Theseus is also developing a fourth-generation, selective epidermal growth factor receptor (EGFR) inhibitor for C797S-mediated resistance to first- or later-line osimertinib treatment in patients with non-small cell lung cancer (NSCLC).
treatment cancer gastrointestinal lung cancer lungs t-cell
add to watch list Paper trade email alert is off
Press-releases
Theseus Pharmaceuticals Announces Closing of Tender Offer
Published: 2024-02-14 (Crawled : 13:30) - prnewswire.com
THRX | $4.06 0.49% 0
|
| Email alert
Add to watchlist
pharmaceuticals
Concentra Announces Calculation of Additional Price Per Share and Extension of Expiration Date for Tender Offer for Theseus Pharmaceuticals
Published: 2024-01-30 (Crawled : 13:30) - biospace.com/
THRX | $4.06 0.49% 0
|
|
| O: 1.87%
H: 0.49%
C: -0.49%
pharmaceuticals extension
CAMBRIDGE BANCORP INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Cambridge Bancorp - CATC
Published: 2024-01-22 (Crawled : 21:00) - prnewswire.com
SP | $50.58 -0.39% 46K
|
Commercial Services
|
| O: 0.06%
H: 0.0%
C: -0.39%
EBC | $12.955 -0.96% 170K
|
Finance
|
| O: 0.84%
H: 0.0%
C: -2.65%
CATC | $63.93 0.35% 1.9K
|
Finance
|
| O: 0.46%
H: 0.0%
C: -1.85%
alert
SP PLUS INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of SP Plus Corporation - SP
Published: 2024-01-22 (Crawled : 21:00) - prnewswire.com
SP | $50.58 -0.39% 46K
|
Commercial Services
|
| O: 0.06%
H: 0.0%
C: -0.39%
CATC | $63.93 0.35% 1.9K
|
Finance
|
| O: 0.46%
H: 0.0%
C: -1.85%
corporation alert plus
THESEUS PHARMACEUTICALS INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Theseus Pharmaceuticals, Inc. - THRX
Published: 2024-01-22 (Crawled : 21:00) - prnewswire.com
SP | $50.58 -0.39% 46K
|
Commercial Services
|
| O: 0.06%
H: 0.0%
C: -0.39%
CATC | $63.93 0.35% 1.9K
|
Finance
|
| O: 0.46%
H: 0.0%
C: -1.85%
pharmaceuticals alert
Theseus Pharmaceuticals Enters into Agreement to Be Acquired by Concentra Biosciences for between $3.90 and $4.05 in Cash per Share Plus a Contingent Value Right
Published: 2023-12-22 (Crawled : 13:30) - biospace.com/
THRX | $4.06 0.49% 0
|
|
| O: 7.09%
H: 0.0%
C: 0.0%
pharmaceuticals plus acquired agreement
Theseus Pharmaceuticals Confirms Receipt of Unsolicited Expression of Interest from Foresite Capital, LLC and OrbiMed Advisors LLC and Unsolicited Proposal from Concentra Biosciences LLC
Published: 2023-11-27 (Crawled : 14:00) - biospace.com/
THRX | $4.06 0.49% 0
|
| Email alert
Add to watchlist
unsolicited pharmaceuticals proposal
Theseus Pharmaceuticals Announces Process to Explore Strategic Alternatives
Published: 2023-11-13 (Crawled : 21:00) - prnewswire.com
THRX | $4.06 0.49% 0
|
| Email alert
Add to watchlist
pharmaceuticals
Theseus Pharmaceuticals Announces Business Highlights and Reports Second Quarter 2023 Financial Results
Published: 2023-08-10 (Crawled : 11:00) - prnewswire.com
THRX | $4.06 0.49% 0
|
|
| O: -0.93%
H: 6.27%
C: 2.51%
business pharmaceuticals financial results
Theseus Pharmaceuticals to Discontinue Enrollment in Phase 1/2 Study and Terminate Development of THE-630 in Patients with GIST
Published: 2023-07-13 (Crawled : 20:00) - prnewswire.com
THRX | $4.06 0.49% 0
|
|
| O: -66.39%
H: 2.19%
C: -16.88%
the-630 pharmaceuticals study
Last 15 days Sec forms
| File Id | Form | Published Date | Transaction Date | Direction | Code | Amount Transacted | Owned Amount |
Your Today's Watch List
Sign in to create a watchlistGainers vs Losers
| 58% | 42% |
Top 10 Gainers
CSSE 4 | $0.3686 142.02% 76M
|
Consumer Services
CZOO | $11.685 134.17% 7.6M
|
BOF | $1.93 64.96% 55M
|
AMST | $3.14 57.0% 59M
|
Technology Services
LICN | $0.7885 40.8% 11M
|
TROO | $1.51 38.53% 5.6M
|
Manufacturing
MULN | News | $3.7 35.53% 6.4M
|
Information
WHLM | $6.61 30.12% 400K
|
Commercial Services
RILY | $27.91 28.5% 8.9M
|
Finance
RBBN 4 | $3.25 26.46% 1.5M
|
Electronic Technology
Last 48 Hours Insiders Buying
MNSB P 310 | $15.785 -3.52% 7.8K
|
Finance
|
15:30
TPL P 3 | $585.24 -0.44% 8K
|
Miscellaneous
|
15:01
ISBA P 966 | $18.0001 3.1K
|
Finance and Insurance
|
15:01
MEGI | $11.97 -0.08% 42K
|
|
00:30
CTRN P 29000 | $22.445 0.97% 16K
|
Retail Trade
|
22:00
CONN | $3.75 1.35% 19K
|
Retail Trade
|
21:30
TGEN P 6000 | $0.685 6.6K
|
Utilities
|
18:30
CMTV P 700 | $16.59 1K
|
Finance and Insurance
|
18:30
FNB | $13.565 -0.48% 210K
|
Finance
|
17:30
RMCF | $3.54 410
|
Consumer Non-Durables
|
20:10